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Abstract
Two populations of human natural killer (NK) cells can be identified in peripheral blood. The majority are CD32CD56dim cells
while the minority exhibits a CD32CD56bright phenotype. In vitro evidence indicates that CD56bright cells are precursors of
CD56dim cells, but in vivo evidence is lacking. Here, we studied NK cells from a patient that suffered from a melanoma and
opportunistic fungal infection during childhood. The patient exhibited a stable phenotype characterized by a reduction in
the frequency of peripheral blood CD32CD56dim NK cells, accompanied by an overt increase in the frequency and absolute
number of CD32CD56bright cells. These NK cells exhibited similar expression of perforin, CD57 and CD158, the major
activating receptors CD16, NKp46, NKG2D, DNAM-1, and 2B4, as well as the inhibitory receptor CD94/NKG2A, on both
CD56bright and CD56dim NK cells as healthy controls. Also, both NK cell subpopulations produced IFN-c upon stimulation
with cytokines, and CD32CD56dim NK cells degranulated in response to cytokines or K562 cells. However, upon stimulation
with cytokines, a substantial fraction of CD56dim cells failed to up-regulate CD57 and CD158, showed a reduction in the
percentage of CD16+ cells, and CD56bright cells did not down-regulate CD62L, suggesting that CD56dim cells could not
acquire a terminally differentiated phenotype and that CD56bright cells exhibit a maturation defect that might result in a
potential altered migration pattern. These observations, support the notion that NK cells of this patient display a
maturation/activation defect that precludes the generation of mature NK cells at a normal rate accompanied by CD56dim NK
cells that cannot completely acquire a terminally differentiated phenotype. Thus, our results provide evidence that support
the concept that in vivo CD56bright NK cells differentiate into CD56dim NK cells, and contribute to further understand human
NK cell ontogeny.
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Introduction
Natural Killer (NK) cells exert cytotoxic functions and secrete
IFN-c and other pro-inflammatory cytokines against virus-infected
and tumor cells. Also, NK cells are key regulators of the adaptive
immune response through their cross talk with dendritic cells
(DCs) that promotes DC maturation, and T helper (Th) 1- and
cytotoxic T lymphocyte (CTL)-mediated immunity [1,2]. NK cell
activity is regulated by cytokines such as interleukin (IL)-2, IL-12,
IL-15, IL-18 and type I interferons (IFNs) [3]. NK cell effector
function is also triggered upon recognition of target cells through
activating receptors such as NKG2D, DNAM-1, 2B4, the Natural
Cytotoxicity Receptors (NCRs) NKp46, NKp44 and NKp30, and
members of the Killer Immunoglobulin-like Receptor (KIR)
family that carry a short cytoplasmic tail (KIR2DS and KIR3DS)
[4,5]. Conversely, normal cells are preserved from NK cell
mediated functions because they promote engagement of inhib-
itory KIR receptors that carry a long cytoplasmic tail (KIR2DL
and KIR3DL), CD94/NKG2A and members of the Immuno-
globulin-Like Transcript (ILT) receptor family [4,5]. Human NK
cells, defined as CD32CD56+ cells, can be subdivided in two main
cell populations. About a 90% are cytotoxic CD56dimCD16+ cells,
while the remaining 10% are CD56brightCD16dim/2 non-cytotoxic
cells that are abundant in secondary lymphoid organs [6,7]. This
subpopulation expresses CD62L (L-selectin) and CCR7, which
directs their homing to these niches but upon activation, CD62L
down-regulation facilitates NK cell trafficking to inflamed tissues
[8].
In vitro evidence indicates that CD56bright NK cells are
precursors of CD56dim NK cells. However, in vivo evidence
about such lineage development is still lacking. As mouse NK
cells are different from human NK cells in many aspects [1],
results from knockout mice cannot be extrapolated to humans.
Conversely, human NK cell deficiencies are helpful to unravel
the immunobiology of NK cells but these conditions are very
rare [9]. Absolute or functional NK cell deficiencies are
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associated with recurrent viral infections [9], confirming their
role as effector cells against such pathogens but deficiencies that
contribute to elucidate NK cell developmental pathways remain
unknown. Here, we describe a human immunodeficiency-like
condition characterized by a reduced frequency of CD32C56dim
cells with lower percentages of terminally differentiated NK cells,
and accumulation of CD32CD56bright cells in peripheral blood
that exhibit altered activation in response to IL-2 and IL-15.
Hence, our results contribute to further unravel human NK cell
ontogeny as we provide strong evidence that support the idea
that in vivo CD56bright NK cells differentiate into CD56dim NK
cells.
Methods
Studies have been approved by the institutional review board
and written informed consent was obtained from the parents of the
patient (as he was not major at the beginning of these studies). In
addition, written consent was obtained from the parents on the
behalf of the minors involved in our study as well as from the
major healthy volunteers that provided blood samples for this
study. Also, all the participants (or the parents of the participants)
of this study gave written consent for the publication of the clinical
data gathered along this investigation.
Antibodies, cytokines and reagents
Recombinant human IL-2, IL-12 and IL-15 were from
PeproTech; recombinant human IL-18 was from MBL Interna-
tional. The following mAbs against human molecules were used:
FITC-, PE- and SPRD-labeled anti-CD3 (UCHT-1, Southern
Biotech); PE/Cy7-labeled anti-CD3 (UCHT-1, Biolegend);
FITC-labeled anti-CD14 (HCD14 Biolegend); PE-labeled anti-
HLA class I (W6/32, Biolegend); PE/Cy5-labeled anti-CD56
(N901, Beckman Coulter); FITC-labeled anti-CD16 (eBioCB16,
eBioscience); FITC-labeled anti-CD57 (HCD57, Biolegend);
FITC- or PE-labeled anti-CD62L (DREG-56, Southern Bio-
tech); FITC-labeled anti-perforin (pfp, dG9, Biolegend); PE-
labeled anti-IFN-c (4S.B3, Biolegend); FITC-labeled anti-
CD107a (1D4B, BD Biosciences); PE-labeled anti-CD25
(BC96, Biolegend); FITC-labeled anti-CD69 (FN50, BD); PE-
labeled anti-NKG2D mAb (clone 1D11, Biolegend); PE-labeled
anti-NKp46 (clone 9E2; Biolegend); FITC-labeled anti-CD226
(DNAM-1, clone DX11, BD Pharmingen); PE-labeled anti-
CD244 (2B4, clone C1.7, Biolegend); PE-labeled anti CD94
(clone DX22; Biolegend); APC-labeled anti-NKG2A (clone
131411, R&D); mAb isotype-matched control mAb (IC,
eBioscience). KIR analysis was performed with a mix of PE-
labeled anti-CD158a, h (EB6.B) and the anti-CD158b1, b2
(GL183) mAbs (both from Beckman Coulter). For regulatory T
cell staining, the Alexa Fluor 488, FoxP3, CD4, CD25 FoxP3
staining kit from BD was used. 7AAD Viability Staining Solution
was from Biolegend.
PBMCs and NK cells
Human peripheral blood mononuclear cells (PBMCs) and NK
cells were isolated from blood of healthy volunteers or from the
patient described in this work (called ‘‘P’’) using Ficoll-PaqueTM
Plus (Amersham Biosciences) centrifugation and the RosetteSep
kit (StemCell), respectively. During the initial testing, we recruited
age-matched healthy donors to compare the patient with these
age-matched samples (hematological data, percentage of NK cells
and CD56dim and C56bright populations). However, as the values
of this age-matched population was similar to the values for adult
population, and considering that the patient reached the age of
17 at the end of this study, in subsequent (retroactive)
experiments we used healthy donors that correspond to young
adults (ages between 25 and 30). Purity of isolated NK cells
(CD32CD56+ cells) was above 90%, as assessed by flow
cytometry (FC). In some experiments, PBMCs were cultured
with IL-2 (0.8 ng/ml) or IL-15 (10 ng/ml) in RPMI 1640 (Sigma)
supplemented with 10% fetal bovine serum (NatoCor, Co´rdoba,
Argentina), sodium pyruvate, glutamine and gentamicin (Sigma)
for up to 5 days.
Figure 1. Lung infection and analysis of blood mononuclear cells. A) CT scan of the lungs of the patient, showing an area of consolidation of
43660 mm in right lower lobe parenchyma (indicated by arrows). B) Lung biopsy (sliced in two pieces) with visible cavitated lesions with
mucoid material. C) Hematoxylin/eosin staining of the lung biopsy showing the infiltration of inflammatory cells with predominance of
histiocytes and multinucleated giant cells containing PAS-positive spherical bodies of 5 to 10 mm in diameter (indicated by arrows). The
morphological characteristics of these PAS-positive spherical bodies are compatible with Cryptococcus neoformans infection. D) Absolute
numbers of total NK cells, CD32CD56dim cells and CD32CD56bright cells in blood of 6 healthy normal donors (N) and in blood from two draws
from different dates (indicated in parentheses) from the patient (P). E) PBMCs from 9 different normal donors (N) and from different blood draws
from different dates (indicated in parentheses) from the patient (P) were stained with anti-CD3 and anti-CD56 mAbs, and the percentage of NK
cells (CD32CD56+ cells), CD32CD56dim and CD32CD56bright cells within the whole mononuclear cell population (PBMCs) were calculated and
depicted as dot plots. Also, the relative abundance of CD32CD56bright and CD32CD56dim cells was calculated and depicted (CD32CD56bright are
shown in black bars; CD32CD56dim cells are shown in white bars). Each sample of the patient was tested at least twice, and individual values
obtained are shown as a dot in the graphs. Interquartile ranges (IQR) are indicated in the graphs of panels D and E. F) Representative dot plots
of lymphoid cells gated according to their FSC and SSC parameters. The numbers in each region correspond to the percentage of CD32CD56dim
and CD32CD56bright cells within the lymphoid population (gated according to their FSC and SSC parameters). G) Representative dot plots to
show the percentage of CD32CD562CD16+ NK cells within the CD32 lymphoid cell population in a healthy normal control (N) and in one sample
of the patient (P). The numbers in each quadrant correspond to the percentage of CD16+CD562, CD16+CD56dim and CD162CD56bright NK cells.
Right graph: data from 3 healthy normal controls and 3 blood samples from different dates from the patient (P). Percentages depicted
correspond to the percentage of CD32CD562CD16+ cells within the total NK cell population (CD16+CD562 + CD16+CD56dim + CD162CD56bright
cells). H) PBMCs from normal donors (N) and from the patient (P) were stained with anti-CD3, anti-CD14 and anti-HLA class I mAbs to assess HLA
class I expression (continuous line) on T cells (CD3+ cells) and monocytes (CD14+ cells). Data presented correspond to representative histograms.
Dashed lines: IC mAb. The numbers inserted in the graphs correspond to the MFI. I) PBMCs from normal donors (N) and from the patient (P)
were stained with anti-CD4, anti-CD25 and anti-Foxp3 to assess the percentage of Tregs. The dot plots correspond to Foxp3 vs. CD25 in CD4+
cells gated from the FSC vs. SSC plots. The percentages in each quadrant are shown. The right graph shows the percentage of Tregs in PBMCs
from 6 healthy normal controls and in two blood samples from different dates (indicated in parentheses) from the patient (P). One
representative experiment from 3 independent analyses is shown in C and D. PBMCs from blood samples obtained in February 2011 were used
for panels F, H and I.
doi:10.1371/journal.pone.0051677.g001
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Flow cytometry and cell sorting
Cells were stained with specific fluorochrome-labeled mAbs,
analyzed in a FACSAria flow cytometer (BD), and data were
processed with the FlowJo software (Tree Star Inc., Ashland, OR).
Numerical data presented are the percentage of cells in the
quadrants in the dot plots or to the geometric mean fluorescence
intensity (MFI) in the histograms. Also, CD32CD56dim and
CD32CD56bright cells were sorted with the FACSAria cell sorter
up to .99% of purity.
IFN-c production by NK cells
PBMCs from normal donors or from the patient were
stimulated overnight at 37uC with IL-12 (10 ng/ml), IL-15
(1 ng/ml) and IL-18 (10 ng/ml). During the last 4 h of culture,
GolgiStop and GolgiPlug reagents (BD) were added, following the
instructions provided by the manufacturer. Thereafter, cells were
stained with anti-CD3 and anti-CD56 mAbs, permeabilized with
Cytofix/Cytoperm (BD) and stained with the anti-IFN-c mAb to
assess IFN-c producing cells within the CD32CD56dim and
CD32CD56bright NK cell subpopulations by FC.
Degranulation of NK cells
NK cells were cultured overnight at 37uC with IL-12, IL-15 and
IL-18 or K562 target cells. During the last 4 h, the anti-CD107a
or an IC mAbs were added together with Golgi-Plug and Golgi-
Stop (BD). Thereafter, cells were stained with anti-CD3 and anti-
CD56 mAbs, and the percentage of CD107a+ cells within the
CD32CD56+ or within the CD32CD56dim cell populations was
determined.
Statistical analysis
A paired t-Student test was used to compare expression of NK
cell receptors between CD32CD56dim and CD32CD56bright cells.
Results
NK cell number and phenotype in blood of a human
patient with melanoma and opportunistic fungal
infection
We studied a case of a pediatric patient (P) that presented
repeated upper airway infections and that at the age of 12
developed an ulcerative spitzoid melanoma in his right ear.
Although the melanoma was successfully removed by surgery, one
year later the patient presented pneumonia in the lower right lobe,
accompanied by fever and bloody stools. A computed tomography
(CT) of the chest revealed the presence of an opaque mass (Fig. 1A)
for which a lung biopsy was taken (Fig. 1B). The analysis of this
biopsy revealed the presence of Cryptococcus neoformans (Fig. 1C).
The fungal infection was non-invasive, there was no evidence
about other infectious agent in the lung to suspect that the
cryptococcosis could have been a super-infection or a case of
commensalism, and patient was successfully treated with flucona-
zol. Nonetheless, the fact that within one year the patient suffered
from a melanoma and a deep fungal infection in the lung led to the
suspicion that the patient might be experiencing some sort of
immunodeficiency. Therefore, further immunological studies were
performed. Standard laboratory tests (Table 1) ruled out classical
primary or secondary immunodeficiencies (this patient was HIV-
negative). Also, subclasses of IgG (IgG1, IgG2, IgG3 and IgG4),
Table 1. Laboratory findings in the patient along time.
Age (years) 13 14 16 17 Reference values
Serum IgG (mg/dl) 1190 1270 1130 1040 984–1544
Serum IgA (mg/dl) 290 247 112 144 112–252
Serum IgM (mg/dl) 196 80 100 91 82–220
Anti-TT Ab (UI/ml) * 0.5 0.8 ND { ND .0.1
Anti- pnemococcus Ab (mg/dl) 88 270 216 139 .113 {
Anti-measles virus Ab + ND ND ND
Anti-HIV Ab 2 2 ND ND
Granulocyte percentage in
whole blood
72 54 58 49 40–80%
Monocyte percentage in
PBMCs (cells/mm3)
7 (168) 8 (156) 8 (208) 8 (557) 4–13%
T cell percentage in PBMCs (cells/mm3)
CD3+ 57 (1368) 66 (1289) 66 (1719) 58 (4041) 65–85%
CD4+ 32 (768) 39 (729) 36 (936) 35 (2450) 36–46%
CD8+ 19 (456) 23 (430) 25 (650) 20 (1400) 19–40%
B cell percentage in PBMCs (cells/mm3)
CD20+ 28 (672) 24 (467) 20 (520) 26 (1812) 7–23%
Proliferative response (cpm)
PHA 40000 115000 ND ND 74.000–135.000
ConA 79000 101000 ND ND 54.000–104.000
Anti-CD3 46000 180000 ND ND 55.000–91.000
PMA + Ionomycin 69000 275000 ND ND 61.000–149.000
DTH N 1 ND ND ND
*TT: Tetanus toxoid; {ND: not determined; {As established by the Argentinean Society of Pediatrics; 1N: normal.
doi:10.1371/journal.pone.0051677.t001
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antibody activity and complement activity were normal. The
patient was Purified Protein Derivative from Mycobacterium
tuberculosis (PPD)-negative and had a complete vaccination
schedule with no adverse reactions. Although the patient did not
show further medical problems, periodic blood examination
covering a period of 4 years revealed a slight decrease in the
percentage of CD3+ cells within PBMCs at the age of 13 and 17,
accompanied by reduced proliferative response against PHA or
anti-CD3 stimulation, absolute numbers of NK cells that were
within the range of healthy individuals but an altered frequency of
CD32C56dim and CD32C56bright NK cells in peripheral blood
when compared to healthy normal controls (Fig. 1D, left graph and
Fig. 1E). However, only the altered frequency of NK cells was
stable and consistent along time. Therefore, we centered our
efforts in a deeper analysis of this cell compartment. This reduced
frequency of peripheral blood NK cells was mostly due to the
presence of reduced percentages of CD56dim NK cells (Fig. 1D
and 1E) accompanied by increased percentages and absolute
numbers (cells/mm3) of CD56bright NK cells in PBMCs (Fig. 1D–
F). These results indicate that this patient exhibits a stable
phenotype characterized by an accumulation of CD32CD56bright
cells accompanied by a reduction in CD32CD56dim cells in
peripheral blood and suggest that there could be a blockade in the
transition of CD32CD56bright cells to CD32CD56dim cells in vivo.
A more detailed analysis revealed that the patient also seems to
exhibit an accumulation of CD32CD562CD16+ NK cells
(Fig. 1G).
Accumulation of CD56bright NK cells has been observed in
certain TAP deficiencies and after treatment with Daclizumab, a
humanized anti-CD25 mAb [10]. TAP deficiencies cause
reduced expression of HLA class I molecules, but unaltered
amounts of HLA class I molecules were detected on T cells and
monocytes of this patient (Fig. 1H). Daclizumab interferes with
the IL-2 signaling, which is a pathway necessary to generate
regulatory T cells (Treg, CD4+CD25+Foxp3+ cells). However,
this patient exhibited percentages of CD4+CD25+Foxp3+ cells in
peripheral blood that were similar to healthy normal donors
(Fig. 1I). Thus, this patient does not seem to exhibit a TAP
deficiency and it is unlikely that he exhibits a blockade in the IL-2
signaling pathway.
To further characterize NK cells from this patient, we
performed phenotypic and functional studies. A phenotypic
analysis demonstrated percentages of perforin+, CD16+, CD57+,
CD158+ and CD62L+ cells within the CD56dim and CD56bright
cell populations similar to healthy donors, as well as slightly
reduced percentages of CD57+CD158+ cells within the total NK
cell population and also within gated CD32CD56dim NK cells,
when compared to healthy controls (Fig. 2 and Table 2). In
addition, we analyzed the expression of a large panel of NK cell
receptors on CD56bright and CD56dim NK cells (Fig. 3). We
observed higher amounts of CD16 on CD56dim cells than on
CD56bright cells from both, healthy controls and the patient, and
these differences were statistically significant (expression on
CD56dim vs. CD56bright NK cells: p,0.01 for healthy donors
and p,0.001 for the patient). Conversely, we observed higher
amounts of NKp46, NKG2D, CD94 and NKG2A on CD56bright
cells than on CD56dim cells from both, healthy controls and the
patient. The higher expression of NKp46, NKG2D, CD94 and
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Figure 2. Phenotype of NK cells. A) PBMCs from two normal
(healthy) donors (N1 and N2) and from the patient (P) were stained with
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(KIR) or anti-CD62L, and fluorescence derived from this third
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NK cells as CD32CD56+ as dot plots. B) Expression of CD57 and CD158
in NK cells (depicted as dot plots and gated as CD32CD56+ cells) from
N1, N2 and the patient (P), and on CD32CD56dim cells from P. The
percentage in each quadrant is shown. Results correspond to one from
3 independent experiments. PBMCs from blood samples obtained in
May 2007 were used.
doi:10.1371/journal.pone.0051677.g002
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NKG2A on CD56bright NK cells than on CD56dim cells were
statistically significant for each receptor and for NK cells from
healthy donors or from the patient (p,0.05 in all cases).
Conversely, the expression of DNAM-1 and 2B4 were similar
on CD56bright NK cells and CD56dim cells from healthy donors
or from the patient. Besides the different expression of CD16,
NKp46, NKG2D, CD94 and NKG2A on CD56bright vs.
CD56dim cells, no differences were observed in their expression
between CD56bright NK cells from the patient when compared to
CD56bright NK cells from healthy donors, and between CD56dim
NK cells from the patient when compared to CD56dim NK cells
from healthy donors. In addition, functional analysis revealed
that CD32CD56dim and CD32CD56bright cells of this patient
produced IFN-c in response to IL-12, IL-15 and IL-18 (Fig. 4A).
Although it appeared that CD56bright cells from the patient
produced more IFN-c than the healthy controls, the sample size
was not enough to decide whether this difference was statistically
significant. Besides, these results indicate that the patient’s NK
cells do not exhibit a defect in the capacity to produce IFN-c.
Moreover, NK cells and CD56dim NK cells of the patient also
did not exhibit an alteration in the degranulation capacity
(expression of cell surface CD107a) after stimulation of NK cells
with IL-12, IL-15 and IL-18 or after co-culture with K562 cells
(Fig. 4B).
These results suggest that this patient exhibits an altered
frequency of NK cells, an increase in the absolute numbers of
CD56bright NK cells in blood, and CD56dim NK cells that exhibit a
slightly reduced percentage of terminally differentiated cells
(CD57+CD158+) but with unaltered expression of the main
receptors involved in NK cell activation (CD16, NKp46, NKG2D
and DNAM-1) and regulation (CD94/NKG2A), and in their IFN-
c production and degranulation in response to cytokines or K562
cells.
Inappropriate in vitro maturation/activation of NK cells in
response to cytokines supports in vivo differentiation of
CD56bright cells into CD56dim cells
Next, PBMCs of the patient were stimulated with IL-2 or IL-15
and expression of the same cell surface markers as in resting NK
cells was assessed (Fig. 5 and Table 2). We observed that upon
stimulation with IL-2 or with IL-15, CD56bright NK cells from the
patient up-regulated expression of perforin (Fig. 5), CD25 (the a
chain of the high affinity receptor of IL-2, not shown), and CD69
(not shown) in a similar manner as NK cells from healthy donors.
However, upon stimulation with these cytokines, CD56bright NK
cells of the patient remained clearly distinguishable from
CD56dim NK cells in the dot plots (compare Fig. 2 to Fig. 5B
and Fig. 5D). Conversely, it was hard to distinguish the
CD56bright NK cells from the CD56dim NK cells in healthy
donors, appearing both as only one CD56+ homogeneous cell
population.
Moreover, less CD56dim NK cells from the patient, compared to
healthy controls, acquired CD57 and CD158 upon stimulation
with IL-2 or IL-15 (Fig. 5A and 5B, and Fig. 6A). Also, a
substantial fraction of CD56dim cells showed a reduction in the
percentage of CD16+ cells (Fig. 6A and Table 2), and less total NK
cells and CD56dim cells from the patient, compared to healthy
controls, became CD57+CD158+ upon stimulation with IL-2 or
IL-15 (Fig. 5B, Fig. 5E and Fig. 6B). Overall, these results suggest
that in the patient, less NK cells could progress to an activated
phenotype and acquire a terminally differentiated phenotype in
response to IL-2 or IL-15. In addition, we observed that
CD32CD56bright cells of the patient exhibited a defective down-
regulation of CD62L upon stimulation with IL-2 (Fig. 5A, Fig. 6C
and Table 2) that was not due to a slower kinetic of CD62L down-
regulation as even at prolonged stimulation periods with IL-2 or
IL-15, more than 60% of CD32CD56bright NK cells of the patient
while less than 20% of CD32CD56bright cells from healthy
controls remained CD62L+ (Fig. 6D). Of note, the inability to
down-regulate CD62L and the sustained high expression of CD56
was not due to apoptosis induction as CD56bright NK cells
remained viable after 5 days of stimulation with IL-15 (not shown).
Experiments performed with sorted CD56dim and CD56bright NK
cells stimulated with IL-2 revealed that both NK cell subpopula-
tions (from the patient and from the healthy control that was
simultaneously analyzed) up-regulated CD56 expression (Fig. 5C).
However, sorted CD56dim cells from healthy controls and from the
patient did not up-regulate CD158 in response to IL-2, while
sorted CD56dim and CD56bright cells did not down-regulate
expression of CD62L. These results indicate that IL-2 alone
cannot provide sufficient maturation signals to sorted NK cell
subpopulations.
In summary, the results presented suggest that this patient
exhibits a clinical picture that is compatible with a novel
immunodeficiency-like condition characterized by a) low frequen-
cy of CD56dim NK cells in peripheral blood that cannot properly
acquire expression of, CD57 and CD158, and maintain expression
of CD16 upon stimulation with IL-2 or IL-15; and b) an increase
in the frequency and absolute numbers of CD56bright NK cells that
do not down-regulate CD62L upon stimulation with these
cytokines. Overall, these data might suggest the existence of a
defect that compromises NK cell maturation and activation and
support the idea that in vivo CD32CD56bright cells differentiate into
CD32CD56dim NK cells.
Discussion
NK cells are pivotal players of the immune response against
tumors and viruses in humans and mice. Although much
information about NK cell lineage development has been obtained
using genetically modified animals, information about human NK
cell ontogeny is limited mostly due to the scarcity of human NK
cell deficiencies. Some data have emerged from studies performed
in blood of patients after bone marrow transplantation [11]. Also,
four NK cell developmental intermediates have been indentified in
human lymph nodes and tonsils [12]. However, an open and
important question is whether CD56dim and CD56bright NK cells
belong to separate lineages of whether CD56bright NK cells are
immature precursors of CD56dim NK cells. In vitro evidence favors
the second possibility [10,13–18], but in vivo evidence is still
lacking. Here, we describe the first human immunodeficiency-like
Figure 3. Expression of NK cell receptors. PBMCs from at least 3 different normal(healthy) donors (N) and from different blood draws from
different dates (indicated in parentheses) from the patient (P) were stained with anti-CD3, anti-CD56, and anti-CD16, anti-NKp46, anti-NKG2D, anti-
DNAM-1, anti-CD94, anti-NKG2A or anti-2B4 as described in Methods. Fluorescence derived from the third fluorochrome-labeled mAb on
CD32CD56bright or CD32CD56dim cells was depicted. Representative histograms are shown on the left with the corresponding MFI inserted in the
histrogam, while the MFI for each receptor of the healthy normal donors and the 2 different samples of the patient are depicted on the right graphs.
PBMCs from blood samples obtained in December 2011 were used.
doi:10.1371/journal.pone.0051677.g003
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condition characterized by low frequency of CD56dim NK cells
with an overt and persistent increased frequency and absolute
numbers of CD56bright NK cells in peripheral blood. This
particular phenotype was accompanied by a slight increased
frequency of CD32CD562CD16+ NK cells, which are expanded
during chronic viral infections, are thought to be a source of
chemokines relevant for anti-viral immunity, and tentatively derive
from CD56dim NK cells [19].
Increased percentage of CD56bright NK cells with normal
numbers of total NK cells have been observed in different
physiological and pathological conditions [20–24], but none of
them seem to be plausible in the patient herein studied. Recently,
two reports described mutations in the minichromosome mainte-
nance complex component 4 (MCM4) that caused NK cell
deficiency and adrenal insufficiency [25,26]. In one report,
reduced NK cell numbers were observed but their phenotype
and function was not investigated [26]. In the other report it was
observed that the patients that carry the mutation exhibited
reduced amounts of CD56dim NK cells and lower percentages of
pfp+, CD57+ and CD94med/low/2 NK cells in blood, and it was
concluded that CD56bright NK cells are largely depend on MCM4
to proliferate and generate C56dim NK cells [25]. However,
normal amounts of CD56bright NK cells in blood of the patients
were detected. Conversely, in the patient that we present in this
work, a consistent increase in absolute counts of CD56bright NK
cells was detected and he did not exhibit a growth retardation or
adrenal insufficiency.
A detailed phenotypic analysis of NK cells from our patient
revealed percentages of perforin+, CD16+, CD57+, CD158+ within
the CD56dim subpopulation, and CD62L+ cells within the
CD56bright subpopulation that were similar to healthy donors.
However, the patient exhibited slightly decreased percentages of
CD57+CD158+ CD56dim NK cells. Expression of CD57 and
CD158 has been associated with the acquisition of a terminally
differentiated phenotype by NK cells [27,28,29] for which it
appears that the patient presents less terminally differentiated NK
cells in peripheral blood. Also, CD56dim and CD56bright NK cell
subpopulations expressed unaltered amounts of the main receptors
involved in NK cell activation (CD16, NKp46, NKG2D and
DNAM-1) and regulation (CD94/NKG2A), and did not exhibit a
defect in IFN-c production upon stimulation with IL-12, IL-15
and IL-18. Also, CD32CD56dim NK cells did not present an
altered degranulation in response to cytokines and K562 cells.
Since we observed a decrease in CD56dim NK cell frequency with
a concomitant increase in the frequency and absolute numbers of
CD56bright NK cells in peripheral blood, we reasoned that the
patient may course with a mild immunodeficiency that affects NK
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presented correspond to CD32CD56+ gated cells from one healthy
normal donor and from one sample of the patient. Lower graph:
individual data from three healthy normal donors and from two
different samples of the patient. B, C) NK cells from a healthy normal
donor (N) or from the patient (P) were cultured overnight in the
absence (Resting) or in the presence of IL-12, IL-15 and IL-18 (+
Cytokines) or K562 cells at an 1:1 ratio (+ K562), and cell surface
CD107a (red histograms) was assessed on gated CD32CD56+ cells (B)
or on gated CD32CD56dim cells (C) by FC and depicted as histograms.
The numbers in the histograms indicate the percentage of CD107a+
cells. Markers were set with cells stained with the IC mAb (black
histograms) to leave less than 1% of positive cells. Experiments were
repeated twice with NK cells from two different healthy donors and
two different blood draws from the patient with similar results.
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panels B and C.
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cell maturation of CD56bright cells and, eventually, activation of
CD56dim cells. Surprisingly, stimulation of PBMCs of this patient
with IL-2 or IL-15 led to three major observations. First, the
CD56bright NK cell subpopulation remained clearly visible and
distinguishable from the CD56dim NK cell subpopulation.
Second, these CD56bright NK cells could not down-regulate
CD62L upon stimulation with IL-2 or IL-15 but remained
viable. And third, only a small fraction of CD56dim NK cells
acquired CD57 and CD158 upon stimulation with IL-2 or IL-
15, while a reduction in the percentage of CD56dimCD16+ was
observed. Although this difference indicates that some results
obtained in vitro with cytokine-stimulated NK cells may not
reflect an in vivo situation, our results indicate that CD56bright
cells of this patient could not progress along the normal pathway
of maturation and that part of the CD56dim NK cell pool of the
patient could not acquire a terminally differentiated phenotype
characterized by up-regulated expression of CD16, CD57 and
CD158 [28,29,30]. The unusual behavior of the patient’s NK
cells was observed when IL-2 stimulations were performed using
whole PBMCs. When sorted CD32CD56dim and
CD32CD56bright cells were stimulated, we were unable to
observe up-regulation of CD158 on CD56dim cells and down-
regulation of CD62L on CD56bright from the patient and from
the healthy control, suggesting that NK cells require more
complex signals than IL-2 alone to trigger differentiation and
maturation.
Previous reports [31,32,33] described the existence of a small
subpopulation of CD56bright NK cells characterized by the
expression of CD16 (CD56brightCD16+) that would be a
maturation intermediate. We may speculate that the blockade
in the differentiation of CD56bright cells into CD56dim cells in
the patient affects a fraction of the CD56brightCD162 cells
during their transition to CD56brightCD16+ cells because the
former cells remain detectable upon stimulation with IL-2 or IL-
15. On the other hand, down-regulation of CD62L and CD16
have been associated with the secretion and proteolytic activity
of matrix metalloproteinases [34,35]. As only CD56bright NK
cells but not CD56dim NK cells exhibited defective down-
regulated CD62L, it is very unlikely that the patient may display
a defect in these enzymes. CD62L directs the traffic of
CD56bright cells to lymph nodes, where they down-regulate
CD62L upon activation, facilitating the migration of NK cells to
inflamed tissues. As CD56bright NK cells from the patient failed
to down-regulate CD62L upon stimulation, we suggest that they
probably may traffic normally into lymph nodes but once they
sense activating stimuli, they may display an altered trafficking
pattern due to such faulty down-regulation of CD62L. This
situation may lead to a weakened immunosurveillance of
peripheral tissues exposed to environmental pathogens (such
as skin and mucosa), which could have contributed to the
development of a melanoma and the opportunistic fungal
infections at these sites.
Of note, as the altered NK cell phenotype and response to
cytokines described is partial and a fraction of NK cells from the
patient achieved terminal differentiation, we suggest that he
carries some sort of mild immunodeficiency or immunodefi-
ciency-like condition that is probably the result of a heterozy-
gous genotype that generates a ‘‘bottleneck’’ (instead of a
complete blockade) that precludes CD56dim NK cell develop-
ment and activation at rates similar to healthy individuals. Such
putative heterozygous genotype would preclude normal differ-
entiation of CD56bright cells to CD56dim cells and in the
acquisition of a CD62Llow/2CD16+CD57+CD158+ phenotype
by CD56dim cells but would allow a sufficient number of NK
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cells to mature adequately and respond to activation stimuli,
which in turn would provide a sufficient degree of NK cell
activity to protect the patient from suffering major infections, in
particular viral infections that are characteristic in patients with
absolute or severe functional defects in NK cells [9]. Despite
these speculations, our results provide evidence that indicates
that in vivo, CD56bright cells differentiate into CD56dim NK cells,
which constitute a contribution to a better understanding of NK
cells ontogeny in humans.
Figure 5. Phenotype of NK cells stimulated with IL-2 or IL-15. PBMCs from two healthy normal donors (N1 and N2) and from the patient (P)
(A, B) or sorted CD56dim and CD56bright NK cells from one healthy normal donor and from the patient (C) were stimulated for 3 days with IL-2. Also,
PBMCs from two healthy normal donors (N1 and N2) and from the patient (P) were stimulated for 3 days with IL-15 (D, E). Thereafter, cells were
harvested and stained with anti-CD3 and anti-CD56, and a third fluorochrome-labeled mAb (indicated on the y-axis). Also, expression of CD57 and
CD158 in NK cells (gated as CD32CD56+ cells) from N1, N2 and the patient (P), and on CD32CD56dim cells from P was plotted for cells stimulated with
IL-2 or IL-15 (B, E). Expression of CD57 and CD158 on sorted and IL-2-stimulated CD56dim NK cells from one healthy normal donor and from the
patient is also shown (C). Data are depicted as dot plots. The percentages in each quadrant are shown. Results correspond to one from 3
independent experiments.
doi:10.1371/journal.pone.0051677.g005
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Figure 6. Percentage of CD16+, CD57+, CD158+ and CD62L+ NK cells before and after stimulation with IL-2 or IL-15. A) Percentage
of CD16+, CD57+ and CD158+ cells before (2) and after stimulation of PBMCs with IL-2 or IL-15 (+) in total NK cells (CD32CD56+ cells, upper line
of graphs) and in CD56dim NK cells (lower lane of graphs) from healthy normal donors (blue) and from the patient (red). B) Percentage of
CD57+CD158+ cells before (2) and after stimulation of PBMCs with IL-2 or IL-15 (+) in total NK cells (CD32CD56+ cells) and in CD56dim NK cells
from the same samples. Blue: NK cells from healthy donors; red: NK cells from the patient; green: CD32CD56dim NK cells from the patient. C)
Percentage of CD62L+ cells before (2) and after stimulation of PBMCs with IL-2 (+) in CD32CD56dim cells and in CD32CD56bright cells from the
same samples. Blue: CD32CD56+ cells from healthy donors; red: CD32CD56+ cells from the patient; green: CD32CD56dim cells from the patient.
D) Percentage of CD62L+ cells before (0) and after 3 to 5 days of stimulation of PBMCs with IL-2 (left graph) or IL-15 (right graph) in
CD32CD56dim and CD32CD56bright NK cells from healthy donors and from the patient. Black: CD32CD56dim cells from healthy donors; green:
CD32CD56dim cells from the patient; blue: CD32CD56bright cells from healthy donors; red: CD32CD56bright cells from the patient. Six healthy
donors samples were used for analysis of CD16 and CD57; two healthy donor samples were used for analysis of CD158, CD57 and CD62L
expression. One representative experiment from 3 independent analyses is shown. PBMCs from blood samples obtained in December 2007 were
used.
doi:10.1371/journal.pone.0051677.g006
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